All news

Applicable resale coverage survives as Allarity Therapeutics (ALLR) ends its Tumim stock sale agreement.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Allarity Therapeutics, Inc. (ALLR) terminated its Common Stock Purchase Agreement with Tumim Stone Capital LLC, effective October 28, 2026, ending a primary offering of up to $6 million in common stock. This termination, however, does not affect resale coverage for shares already issued to Tumim or withdraw the Form S-3 registration statement.

Read original source

ALLR company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.